 Scaling The Peaks Biotech Stocks Hitting 52-week Highs July 30 Achieve Life Sciences Inc NASDAQ: ACHV Annexon Inc NASDAQ: ANNX IPOed July 24 Atossa Therapeutics Inc NASDAQ: ATOS Bio-Rad Laboratories, Inc. NYSE: BIO Bio-Rad Laboratories, Inc. Class B NYSE: BIO-B Catalent Inc NYSE: CTLT Dr.Reddys Laboratories Ltd NYSE: RDY Edesa Biotech Inc NASDAQ: EDSAannounced filing of an IND for a Phase 23 study of a COVID treatment candidate Hologic, Inc. NASDAQ: HOLX Horizon Therapeutics PLC NASDAQ: HZNP Immunic Inc NASDAQ: IMUX Ligand Pharmaceuticals Inc. NASDAQ: LGND Merit Medical Systems, Inc. NASDAQ: MMSI NeoGenomics, Inc. NASDAQ: NEO OraSure Technologies, Inc. NASDAQ: OSUR Penumbra Inc NYSE: PEN Precipio Inc NASDAQ: PRPO announced a distribution agreement for its FDA-authorized COVID-19 serology antibody tests Repligen Corporation NASDAQ: RGEN TIZIANA LF SCIES ADR NASDAQ: TLSA Veracyte Inc NASDAQ: VCYT Zoetis Inc NYSE: ZTSDown In The Dumps Biotech Stocks Hitting 52-week Lows July 30 Acorda Therapeutics Inc NASDAQ: ACOR Genfit SA NASDAQ: GNFT Gritstone Oncology Inc NASDAQ: GRTS Happiness Biotech Group Ltd NASDAQ: HAPP Orchard Therapeutics PLC - ADR NASDAQ: ORTX ORIC Pharmaceuticals Inc NASDAQ: ORIC Pandion Therapeutics Holdco LLC NASDAQ: PAND RA Medical Systems Inc NYSE: RMED Sonnet BioTherapeutics Holdings, Inc. NASDAQ: SONN Tricida Inc NASDAQ: TCDA Verrica Pharmaceuticals Inc NASDAQ: VRCAStocks In Focus PfizerBioNTech Agrees to Supply 120M Doses of Coronavirus Vaccine to Japan Pfizer Inc. NYSE: PFE and BioNTech SE - ADR NASDAQ: BNTX announced an agreement with the Ministry of Health, Labour and Welfare in Japan to supply 120 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, subject to clinical success and regulatory approval, beginning in the first half of 2021.The companies have already signed agreements with the U.K. and U.S. governments for supplying BNT162.Tiziana Applies For Patent For Nasal Administration of its Monoclonal Antibody as a Potential COVID-19 Cure Tiziana said it has submitted a patent application for the potential use of nasally administered Foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of COVID-19, either alone or in combination with other anti-viral drugs.The stock was soaring 47.53 to 7.30 in pre-market trading Friday.Roches Combo Therapy Gets FDA Nod For Skin Cancer Roche Holdings AG OTC: RHHBY said the FDA approved Tecentriq plus Cotellic and ZelboraF for the treatment of BRAF V600 mutation-positive advanced melanoma patients.SanofiGSK Gets 2.1B U.S. Government Funding For COVID-19 Vaccine Supply Sanofi SA NASDAQ: SNY and GlaxoSmithKline plc NYSE: GSK announced an agreement with the U.S. government under the Operation Warp Speed project, for up to 2.1 billion in funding, more than half of which is to support further development of the vaccine, including clinical trials, with the remainder used for manufacturing scale-up and delivery of an initial 100 million doses of the vaccine. Sanofi will receive the majority of the funding.The U.S. government has a further option for the supply of an additional 500 million doses longer term, the companies said.Axovant Announces Manufacturing Supply Agreement With U.K. Gene Therapy Company Axovant Gene Therapies Ltd NASDAQ: AXGT said its subsidiary has signed a three-year Clinical Supply Agreement with U.K.s Oxford Biomedica plc, under which the latter will manufacture GMP batches for Axovant to support the ongoing and future clinical development of AXO-Lenti-PD, a clinical-stage gene therapy product to treat moderate to severe Parkinsons Disease.JJs Psoriasis Drug Gets Label Expansion; Coronavirus Vaccine Produces Positive Results in Pre-clinical Studies Johnson Johnsons NYSE: JNJ Janssen unit said the FDA approved an expanded indication for Stelara as a treatment for pediatric patients, who struggle with the skin lesions or plaques associated with moderate to severe plaque psoriasis.Separately, JJ announced publication in the journal Nature results of preclinical studies of its adenovirus serotype 26 vector-based vaccine, which showed the investigational vaccine elicited a robust immune response as demonstrated by neutralizing antibodies, successfully preventing subsequent infection and providing complete or near-complete protection in the lungs from the virus in non-human primates. The company expects to commence Phase 3 studies in September.Earnings Corvus Pharmaceuticals Incs NASDAQ: CRVS second-quarter loss narrowed from the year-ago period but was wider than the consensus estimate.The stock fell 6.32 to 4 in after-hours trading.Opko Health Inc. NASDAQ: OPK said its second-quarter revenues increased from 226.4 million to 301.2 million. The company reversed from a loss of 10 cents per share to a profit of 5 cents per share.View more earnings on IBBThe stock lost 6.09 to 5.55 in after-hours trading.Emergent Biosolutions Inc NYSE: EBS reported a 62.3 year-over-year jump in second-quarter revenues and its adjusted EPS exceeded estimates. The company raised its 2020 guidance.The shares were climbing 6.04 to 102.82.Gilead Sciences, Inc. NASDAQ: GILD said its second-quarter revenues fell from 5.7 billion in 2019 to 5.1 billion in 2020. The non-GAAP EPS fell from 1.72 to 1.11, missing the consensus estimate of 1.45. The company raised its product sales and EPS guidance for the full year.Gilead shares were retreating 3.43 to 69.85.DBV TECHNOLOGIES ADR NASDAQ: DBVT reported a higher operating income for the first half but its net loss widened year-over-year.The stock was advancing 8.05 to 4.16.On The Radar PDUFA Dates GW Pharmaceuticals PLC- ADR NASDAQ: GWPH awaits FDA verdict on its sNDA for Epidiolex for the treatment of seizures associated with tuberous sclerosis complex.Earnings AbbVie Inc NYSE: ABBV before the market open ImmunoGen, Inc. NASDAQ: IMGN before the market open GlycoMimetics Inc NASDAQ: GLYC before the market openSee more from Benzinga The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologics Blowout Quarter The Daily Biotech Pulse: Mercks Breakthrough Therapy Designation, Sonoma Surges On Sanitizer News, Sanofi-Glaxo And More The Daily Biotech Pulse: Spectrums Positive Dementia Readout, Pfizer, BioNTech Start Late-Stage Coronavirus Trial, resTORbio Receives COVID-19 FundingC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 